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TO THE EDITOR
Great progress has been made in treat-
ing patients with disseminated BRAF-
mutant melanoma with BRAF inhibitors
(Hauschild et al., 2012). Despite this,
responses tend to be short-lived, and the
majority of patients fail therapy. We
recently demonstrated that most of the
proteins involved in escape from BRAF
inhibitor therapy were clients of the
heat shock protein-90 (HSP90) family
of chaperones (Paraiso et al., 2012;
Smyth et al., 2014). In cell culture
models, the HSP90 inhibitor XL888
overcame acquired BRAF inhibitor
resistance, an effect associated with
decreased expression of receptor
tyrosine kinases platelet-derived growth
factor receptor-β and IGF1R and inhibi-
tion of signaling through the mitogen-
activated protein kinase (MAPK) and
phosphatidylinositol 3 kinase/AKT sig-
naling pathways (Paraiso et al., 2012).
In vivo, XL888 treatment decreased
growth of BRAF inhibitor–resistant
melanoma xenografts (Paraiso et al.,
2012). When used as frontline therapy,
the combination of another HSP90
inhibitor (AT13387) with vemurafenib
prevented escape from BRAF inhibition
in melanoma xenograft models (Smyth
et al., 2014). On the basis of these data,
we recently opened a phase 1 dose-
escalation study of XL888 in combina-
tion with vemurafenib (960mg p.o., b.i.
d.) in patients with unresectable BRAF-
mutant melanoma (NCT01657591).
An initial analysis demonstrated the
combination to be well tolerated, with
early indications of efﬁcacy. Similar to
the experience with single-agent BRAF
inhibitor therapy, patients developed
hyperproliferative/neoplastic cutaneous
lesions, with some notable differences
in incidence. These secondary tumors,
which arise as a result of the paradox-
ical activation of the MAPK pathway in
keratinocytes, can be at least partly
abrogated by the BRAF/MEK inhibitor
combination (Flaherty et al., 2012).
Activating HRAS mutations are found in
up to 71% of these lesions that can take
the form of benign tumors (“BRAF
inhibitor–associated verrucous keratosis”),
verruca vulgaris (VV), keratoacanthoma-
like squamous cell carcinoma (KA-SCC),
and typical SCC (Su et al., 2012). Under
physiological conditions, MAPK signaling
follows the activation of Ras, with the
GTP-bound form of Ras inducing RAF to
form dimers that in turn leads to phos-
phorylation and activation of extracellular
signal–regulated kinase (ERK) and MAPK/
ERK kinase (MEK) (Roring et al., 2012). In
cells with upstream Ras activity, the
formation of RAF dimers also has a role
in paradoxical MAPK signaling (Halaban
et al., 2010; Poulikakos et al., 2010;
Gibney et al., 2013). Mechanistically,
this proceeds through the binding of the
BRAF inhibitor to one RAF protomer that
induces the binding and activation of its
partner RAF molecule, and an increase in
MAPK signaling (Poulikakos et al., 2010;
Gibney et al., 2013). Recently, next-gene-
ration BRAF inhibitors have been devel-
oped that limit the paradoxical activation
of ERK signaling (Le et al., 2013), but
as yet their incidence of associated secon-
dary neoplasms in humans has not been
quantiﬁed.
We report herein the incidence of
biopsy-proven skin lesions occurring in
the ﬁrst 24 weeks of therapy when
vemurafenib was combined with XL888
in increasing doses (Figure 1 and
Supplementary Figure S1 and Supple-
mentary Table S1 online). Lesions sus-
picious for malignancy were biopsied
in routine dermatologic follow-up. All
tissue studies took place as part of an
institutional review board–approved
protocol after patients gave written,
informed consent for tumor biopsies to
be performed and used for research
purposes. The incidence and number of
skin lesions per patient decreased as the
dose of XL888 increased in each of the
four cohorts. In cohort 1 (35 mg p.o.,
b.i.w.), 3/3 patients (100%) developed a
total of 6 lesions (2 melanoma, 1 SCC,
and 3 VV). In cohort 2 (45 mg p.o.,
b.i.w.), 2/3 (66%) patients developed
6 lesions (2 KA, 2 SCC, and 2 VV). In
cohort 3 (90 mg p.o., b.i.w.), 2/3 (66%)
patients had 3 total lesions (2 melanoma
and 1 VV). In cohort 4 (135mg p.o.,
b.i.w.), 2/6 (33%) developed 3 VV
(Figure 1). All secondary melanomas
were negative by immunohistochemis-
try for mutant BRAF (VE-1 antibody,
Ventana, Tucson, AZ) and were NRAS
wild type by sequencing (not shown).
The differences in incidence of SCC/KA
between cohorts 1–3 and cohort 4 were
not statistically signiﬁcant, likely a
reﬂection of the small sample size.
The ﬁnding that no patients in cohort
4 developed SCCs/KAs compares favor-
ably with the 26% incidence of SCC
development previously reported in
patients on single-agent vemurafenib
therapy (Sosman et al., 2012).
We next determined whether XL888
prevented the growth of vemurafenib-
induced skin lesions through the sup-
pression of paradoxical MAPK activa-
tion. Previous studies have shown that
BRAF inhibitors activate phospho-ERK
signaling in NRAS-mutant melanoma
cell lines as well as in SCC cell lines
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that are driven through mutant HRAS
(Kaplan et al., 2010; Su et al., 2012).
The administration of a BRAF inhibitor
has been shown to shorten the latency
of SCC induction in a two-step
carcinogenesis model, an effect rever-
sible through MEK inhibition (Su et al.,
2012). In our studies, treatment of
three NRAS-mutant melanoma cell lines
with vemurafenib (1 μM) increased
levels of phospho-ERK, an effect that
was suppressed following the addition
of XL888 (300 nM) (Figure 2a). These
effects were concentration dependent,
with levels of phospho-ERK being
inhibited at concentrations of XL888
4100 nM (Supplementary Figure S2A
online). The ability of BRAF inhibitors to
activate MAPK signaling is dependent
upon CRAF transactivation (Wan et al.,
2004; Poulikakos et al., 2011). As CRAF
is an HSP90 client protein, we next
asked whether XL888 decreased the
expression of CRAF. As expected, the
decrease in paradoxical ERK activa-
tion observed following combined
vemurafenib+XL888 treatment was
also associated with decreased CRAF
expression in three NRAS-mutant mela-
noma cell lines (Figure 2a). Similarly,
XL888 also suppressed vemurafenib-
driven MAPK signaling in NIH3T3 cells
transformed by HRAS Q61L (Supple-
mentary Figure S2B online), an effect
associated with decreased CRAF
expression (Figure 2b). Taken together,
these data suggest that XL888 pre-
vented the emergence of vemurafenib-
associated skin lesions through the
inhibition of both CRAF transactivation
and paradoxical MAPK signaling. Our
clinical ﬁndings agree with recent
mouse model data showing that topical
HSP90 inhibition inhibits UVR-induced
SCC development (Singh et al., 2015).
Our conclusion is that the HSP90
inhibitor XL888 suppresses paradoxical
MAPK activation in NRAS- and HRAS-
driven in vitro models and is associated
with fewer hyperproliferative cutaneous
lesions in melanoma patients receiving
the combination of vemurafenib and
XL888. These data suggest that the
reduced incidence of cutaneous adverse
events could be used as a biomarker of
HSP90 inhibition in this setting.
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Figure 1. Incidence of secondary skin lesions by dose cohort of XL888. Chart shows the incidence
of hyperproliferative/neoplastic skin lesions (melanoma, squamous cell carcinoma (SCC),
keratoacanthoma (KA), and verruca vulgaris (VV)) stratiﬁed by XL888 dose cohort (cohort 1: 30 mg;
cohort 2: 45mg; cohort 3: 90 mg; and cohort 4: 135mg). Data show the number of lesions of each type for
each individual patient (Pt). Cohort 1 had 7 total events (3/3 patients), cohort 2 had 6 total events
(2/3 patients), cohort 3 had 3 total events (2/3 patients), and cohort 4 had 3 total events (2/6 patients).
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Figure 2. XL888 suppresses paradoxical mitogen-activated protein kinase (MAPK) signaling in
NRAS-mutant melanoma and HRAS-transformed NIH3T3 cells. (a) XL888 prevents the paradoxical
MAPK signaling in three NRAS-mutant melanoma cell lines. IPC-298, M245, and WM1366 cell lines were
treated with vemurafenib (1 μM, 72 hours) in the absence and presence of XL888 (300 nM). Western blots
show total CRAF, phosphorylation of extracellular signal–regulated kinase (p-ERK), and total ERK (t-ERK).
GAPDH, glyceraldehyde-3-phosphate dehydrogenase. (b) XL888 (300 nM) suppressed vemurafenib-driven
(1 μM, 72 hours) paradoxical MAPK signaling in NIH3T3 cells transduced with HRAS Q61L.
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TO THE EDITOR
The shape of the mitochondrial network
results from the cumulative activity of
two opposing processes: fusion and
ﬁssion (Mishra and Chan, 2014). These
processes collaborate to ensure homeo-
static maintenance of mitochondrial
function, cellular bioenergetics, and
commitment to mitosis (Nasrallah and
Horvath, 2014). Although the contribu-
tions of aberrant mitochondrial dyna-
mics in neurodegenerative and cardio-
metabolic diseases are established, little
is known about the contribution of mito-
chondrial dynamics in cancer develop-
ment, prognosis, or treatment.
Recently, a role for dynamin-related
protein 1 (DRP1) was revealed in
oncogenic rat sarcoma-induced cellular
transformation and in cellular responses to
oncogenic mitogen-activated protein
kinase (MAPK) inhibition (e.g., BRAFV600E
(v-Raf murine sarcoma viral oncogene
homolog B) inhibition with PLX-4032)
(Bollag et al., 2010; Serasinghe et al.,
2015). DRP1 is a large cytosolic
guanosine-5′-triphosphosphatase that
induces ﬁssion of the mitochondrial
network (Yoon et al., 2001; Smirnova
et al., 2001). For example, when DRP1 is
phosphorylated at serine 616
(DRP1S616℗), DRP1 localizes to mito-
chondria, undergoes oligomerization,
and initiates membrane scission (Mishra
and Chan, 2014). DRP1S616℗ is directly
induced by ERK1/2 (extracellular signal-
regulated kinase) within the BRAFV600E
pathway leading to chronic mitochondrial
ﬁssion, cancer-associated mitochondrial
dysfunction, and resistance to targeted
therapies (Serasinghe et al., 2015). In
melanoma, DRP1S616℗ status dicho-
tomized wild-type BRAF (BRAFWt) from
BRAFV600E disease, suggesting a mechan-
istic contribution of DRP1S616℗ in
BRAFV600E melanoma (Serasinghe et al.,
2015). On the basis of these observations,
we were interested in determining
whether DRP1S616℗ was prevalent in all
BRAFV600E skin lesions (e.g., nevi) or
whether DRP1S616℗ was indicative of
BRAFV600E melanoma.
To investigate this question, we per-
formed immunohistochemistry for the
BRAFV600E and DRP1S616℗ status on a
cohort of tissues. Benign nevi (68
samples; Figure 1a and Supplementary
Figure S1a online), dysplastic nevi (40Accepted article preview online 1 June 2015; published online 18 June 2015
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